Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Lotiglipron in Healthy Adults
NCT04148209Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants with adverse events, Percentage of participants with safety laboratory test results above/below certain threshold and 2 more. Started Nov 2019; status: completed.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04148209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148209.